Transcatheter Pulmonary Valve (TPV) Market Expected to Exceed USD 2 Billion by 2031 as Adult Congenital Heart Programs Expand Worldwide

[Amsterdam, June 4th, 2025] - According to a new study by Clearview Market Insights (CVMI), the global Transcatheter Pulmonary Valve (TPV) market will soar from USD 880 million in 2024 to USD 2.05 billion by 2031, registering a CAGR of 12.8%.

"Transcatheter valve therapy has moved beyond the aortic position," said Dr. Marieke Janssen, Structural Heart Analyst at CVMI. "With self-expanding platforms now approved for native outflow tracts, TPV is poised for the next wave of growth."

Request Sample @ https://clearviewmarketinsights.com/report-details/global-transcatheter-pulmonary-valve-tpv-market-competitive-intelligence-2019-to-2023-forecast-2024-to-2031-research-report/

Growth Catalysts:
• Rising adult CHD population needing redo interventions.
• Avoidance of repeat sternotomy reducing morbidity and cost.
• Device portfolio expansion - larger diameters and repositionable frames.
• Robust reimbursement across U.S., EU, and Japan.
• Technological synergy with 3D imaging and embolic protection.

Segmentation Snapshot (2024):
By Valve Type Share
• Self Expanding XX%
• Balloon Expandable XX%

By Patient Group Share
• Surgically Placed Conduits XX%
• Native RVOT XX%

By End User Share
• Adult Congenital Centers 51 %
• Pediatric Cardiology Hospitals XX%
• Academic Hospitals XX%

Self-expanding valves lead the market and are projected to achieve a 60% share by 2028 as native RVOT devices gain traction. The segment for surgically placed conduits currently dominates, but the native RVOT segment is expected to grow at a CAGR exceeding 15%, highlighting an unmet need in larger outflow tracts.

Regional Momentum:
• North America - 41 % share; Medicare coverage for Harmony; ACH network expansion.
• Europe - XX%; CE MDR approvals broaden valve choice; Germany tops implant volume.
• Asia Pacific - XX%; China's national CHD registry drives referrals; Japan expands specialist centers.
• LATAM & MEA -XX% combined; Brazil's SUS pilot and UAE Heart Center pave adoption.

Competitive Highlights:
Medtronic retains leadership with its Melody and Harmony portfolios, now covering diameters of 22-30 mm. Edwards Lifesciences increases competitive pressure with larger-diameter trials of the SAPIEN Pulmonic. Venus MedTech has secured a CE mark for its VenusP Valve, addressing the native RVOT gap, while JenaValve and Meril Life advance their pipeline technologies.

Innovation Trends:
• Polymeric & tissue-engineered leaflets for extended durability.
• Steerable delivery catheters reduce fluoroscopy by 25 %.
• AI planning software auto-segments RVOT and simulates valve fit.
• Embolic protection devices adapted from TAVI enter TPV trials.
• Hybrid OR-cath lab integration enables complex redo cases.

Looking Ahead to 2031:
Year Milestone
2026 - Native RVOT valves represent 45 % of EU implants
2027 - First polymer leaflet TPV gains CE mark
2028 - Global TPV annual implants exceed 25,000
2029 - U.S. FDA approves larger diameter SAPIEN Pulmonic 35 mm
2030 - Endocarditis rates decline 30 % with antibiotic eluting stents
2031 - >70 % of RVOT re interventions managed transcatheterly worldwide

For more insights, visit https://clearviewmarketinsights.com/report-store

Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369

About Clearview Market Insights
Clearview Market Insights delivers data driven foresight across structural heart and congenital cardiology markets.

This release was published on openPR.